Vibrational Spectroscopy in Forensic Science: A New Frontier for Biopharmaceutical Drug Authentication

Abstract

The global proliferation of counterfeit biologic medicines poses a growing threat to public health and pharmaceutical integrity. Traditional laboratory-based methods for verifying drug authenticity are often time-consuming, costly, and impractical for real-time or field-based applications. This paper explores the emerging potential of infrared (IR) and Raman spectroscopy for forensic detection and authentication of biologics. While these technologies are currently underutilised in forensic science, advancements in instrumentation and data analysis are rapidly enhancing their sensitivity, portability, and usability. Focusing on protein- and peptide-based therapeutics, the paper reviews the principles and applications of IR and Raman spectroscopy, highlighting their ability to detect structural and compositional differences between authentic and counterfeit biologic drugs. The discussion emphasises the importance of interdisciplinary collaboration between forensic and biopharmaceutical sciences. As counterfeiters become more sophisticated, the integration of non-destructive spectroscopic tools into forensic workflows offers a promising path toward the rapid and reliable screening of biologic drugs in both field and laboratory settings.

Keywords

Counterfeit / Biopharmaceutical / Infrared / Raman

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Funding

This research received no external funding.

Declaration of Competing Interest

The author declares that there are no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] World Health Organisation. Substandard and Falsified Medical Products. 2024. Available online: https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products (accessed on 18 April 2025).

[2] World Health Organisation. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products; World Health Organisation: Geneva, Switzerland, 2017. Available online: https://apps.who.int/iris/handle/10665/331690 (accessed on 2 November 2025).

[3] OECD/EUIPO. Trade in Counterfeit Pharmaceutical Products; Illicit Trade; OECD Publishing: Paris, France, 2020. doi:10.1787/a7c7e054-en.

[4] INTERPOL. Pharmaceutical Crime Operations. Available online: https://www.interpol.int/en/Crimes/Illicit-goods/Pharmaceutical-crime-operations(accessed on 17 April 2025).

[5] FakeMeds Campaign. FakeMeds: Safely Buy Medication Online. 2025. Available online: https://fakemeds.campaign.gov.uk/ (accessed on 18 April 2025).

[6] U.S. Food and Drug Administration. BeSafeRx: Know Your Online Pharmacy. 2016. Available online: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/ (accessed on 18 April 2025).

[7] European Union Intellectual Property Office. The EUIPO Joins Forces with Europol and European Medicines Agency to Combat Fake Medicines. 2025. Available online: https://www.euipo.europa.eu/en/news/the-euipo-joins-forces-with-europol-and-ema-to-combat-fake-medicines (accessed on 18 April 2025).

[8] Isles M. What’s in a word?Falsified/counterfeit/fake medicines—The definitions debate. Med. Access@Point Care 2017, 1, maapoc-0000008. doi:10.5301/maapoc.0000008.

[9] Pathak R, Gaur V, Sankrityayan H, Gogtay J. Tackling counterfeit drugs: The challenges and possibilities. Pharm. Med. 2023, 37, 281-290. doi:10.1007/s40290-023-00468-w.

[10] Fallang H. History and overview of counterfeit drug cases. In Trends in Counterfeit Drugs; Elkins KM, Ed.; CRC Press: Boca Raton, FL, USA, 2023. doi:10.1201/9781003183327-8.

[11] Radkhah H, Anaraki SR, Roudsari PP, Bahri RA, Zooravar D, Asgarian S, et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: A systematic review and meta-analysis. Eat. Weight. Disord.-Stud. Anorex. Bulim. Obes. 2025, 30, 10. doi:10.1007/s40519-025-01720-9.

[12] U.S. Food and Drug Administration. FDA Warns Consumers Not to Use Counterfeit Ozempic (Semaglutide) Found in U. S. Drug Supply Chain. 2025. Available online: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain (accessed on 19 April 2025).

[13] World Health Organisation.Medical Product Alert N°2/2024: Falsified Ozempic (Semaglutide). 2024. Available online: https://www.who.int/news/item/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-(semaglutide) (accessed on 26 April 2025).

[14] Medicines and Healthcare Products Regulatory Agency (MHRA). Falsified Ozempic (Semaglutide) Pens Identified at Two Wholesalers in the UK. 2023. Available online: https://www.gov.uk/government/news/falsified-ozempic-semaglutide-pens-identified-at-two-wholesalers-in-the-uk (accessed on 26 April 2025).

[15] Medicines and Healthcare Products Regulatory Agency (MHRA). Ozempic (Semaglutide) and Saxenda (Liraglutide): Vigilance Required Due to Potentially Harmful Falsified Products. 2023. Available online: https://www.gov.uk/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products (accessed on 26 April 2025).

[16] Jankovic J.Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 2004, 75, 951-957. doi:10.1136/jnnp.2003.034702.

[17] Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J. Am. Acad. Dermatol. 2009, 61, 149-150. doi:10.1016/j.jaad.2008.12.042.

[18] Dawson EF, Pateriya S, Blashinsky ZA, Landa-Galindez A. From Botox party to botulism: A case report and public health warning on adulterated botulinum toxin injection. Cureus 2024, 16, e68016. doi:10.7759/cureus.68016.

[19] Centers for Disease Control and Prevention. CDC Investigating Harmful Reactions to Counterfeit Botox. U.S. Department of Health and Human Services. 2024. Available online: https://www.cdc.gov/media/releases/2024/s0416-Counterfeit-Botox.html (accessed on 22 August 2025).

[20] Sawyer M. Suspected Counterfeit Toxin Linked to Botulism Cases. 2025. Available online: https://aestheticsjournal.com/news/suspected-counterfeit-toxin-linked-to-botulism-cases/ (accessed on 22 August 2025)

[21] Qiu H, Shen J, Tang Y, Ji Q, Lin X, Wu D. A retrospective case series study of illegal cosmetic iatrogenic botulism: Outbreak analysis and response lessons. Aesthetic Surg. J. 2025, 45, 936-946. doi:10.1093/asj/sjaf088.

[22] Kobaidze K, Wiley Z. Botulism in the 21st century: A scoping review. J. Brown Hosp. Med. 2023, 2, 72707. doi:10.56305/001c.72707.

[23] Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: From tissue protection to immune regulation. Cell Death Dis. 2020, 11, 79. doi:10.1038/s41419-020-2276-8.

[24] Salamin O, Kuuranne T, Saugy M, Leuenberger N. Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, potential adverse effects. Mol. Cell. Endocrinol. 2018, 464, 75-87. doi:10.1016/j.mce.2017.01.033.

[25] Qureshi ZP, Norris L, Sartor O, McKoy JM, Armstrong J, Raisch DW, et al. Caveat oncologist: Clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J. Oncol. Pract. 2012, 8, 84-90. doi:10.1200/JOP.2011.000325.

[26] Marchand A, Martin L, Martin J-A, Ericsson M, Audran M. The case of the EPO-poisoned syringe. Drug Test. Anal. 2020, 12, 637-640. doi:10.1002/dta.2757.

[27] Graber E, Reiter EO, Rogol AD. Human growth and growth hormone: From antiquity to the recombinant age to the future. Front. Endocrinol. 2021, 12, 709936. doi:10.3389/fendo.2021.709936.

[28] Baumann GP. Growth hormone doping in sports: A critical review of use and detection strategies. Endocr. Rev. 2012, 33, 155-186. doi:10.1210/er.2011-1035.

[29] Vida RG, Fittler A, Mikulka I, Ábrahám E, Sándor V, Kilár F, et al. Availability and quality of illegitimate somatropin products obtained from the Internet. Int. J. Clin. Pharm. 2017, 39, 78-87. doi:10.1007/s11096-016-0398-y.

[30] U.S. Customs and Border Protection. Operation Stops over 70 Shipments of Counterfeit Human Growth Hormones and Other Dangerous Chemicals. 2025. Available online: https://www.cbp.gov/newsroom/local-media-release/operation-stops-over-70-shipments-counterfeit-human-growth-hormones (accessed on 30 October 2025).

[31] Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7, 335-345. doi:10.1007/s10456-004-8272-2.

[32] Mackey T, Cuomo R, Guerra C, Ling BA. After counterfeit Avastin®—What have we learned and what can be done? Nat. Rev. Clin. Oncol. 2015, 12, 302-308. doi:10.1038/nrclinonc.2015.35.

[33] National Agency for Food and Drug Administration and Control. Public Alert No. 052/2024—Alert of Confirmed Cases of Two Counterfeit Batches of Avastin 400 mg/16 ml manufactured by Roche Diagnostics Public GmbH, Mannheim, Germany. 2024. Available online: https://nafdac.gov.ng/public-alert-no-052-2024-alert-of-confirmed-cases-of-two-counterfeit-batches-of-avastin-400mg-16ml-manufactured-by-roche-diagnostics-public-gmbh-mannheim-germany/ (accessed on 23 August 2025).

[34] World Health Organisation. Medical Product Alert No. 5/2024: Falsified IMFINZI (Durvalumab) Injection 500 mg/10 ml. 2024. Available online: https://www.who.int/news/item/23-12-2024-medical-product-alert-n-5-2024 (accessed on 23 August 2025)

[35] World Health Organisation. Medical Product Alert No. 3/2025: Falsified IMFINZI (Durvalumab) Injection 500 mg/10 mL 2025. Available online: https://www.who.int/news/item/14-05-2025-medical-product-alert-n-3-2025--falsified-imfinzi-%28durvalumab%29-injection-500mg-10ml (accessed on 23 August 2025).

[36] Rathore D, Faustino A, Schiel J, Pang E, Boyne M, Rogstad S. The role of mass spectrometry in the characterization of biologic protein products. Expert Rev. Proteom. 2018, 15, 431-449. doi:10.1080/14789450.2018.1469982.

[37] Huang RY, Chen G. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 6541-6558. doi:10.1007/s00216-014-7924-3.

[38] Skeene K, Khatri K, Soloviev Z, Lapthorn C. Current status and future prospects for ion-mobility mass spectrometry in the biopharmaceutical industry. Biochim. Et Biophys. Acta (BBA)-Proteins Proteom. 2021, 1869, 140697. doi:10.1016/j.bbapap.2021.140697.

[39] Füssl F, Strasser L, Carillo S, Bones J. Native LC-MS for capturing quality attributes of biopharmaceuticals on the intact protein level. Curr. Opin. Biotechnol. 2021, 71, 32-40. doi:10.1016/j.copbio.2021.05.008.

[40] Janvier S, De Spiegeleer B, Vanhee C, Deconinck E. Falsification of biotechnology drugs: Current dangers and/or future disasters? J. Pharm. Biomed. Anal. 2018, 161, 175-191. doi:10.1016/j.jpba.2018.08.037.

[41] Bakker-’t Hart IME, Ohana D, Venhuis BJ. Current challenges in the detection and analysis of falsified medicines. J. Pharm. Biomed. Anal. 2021, 197, 113948. doi:10.1016/j.jpba.2021.113948.

[42] Bunaciu AA, Aboul-Enein HY, Fleschin S. Application of Fourier Transform Infrared Spectrophotometry in Pharmaceutical Drugs Analysis. Appl. Spectrosc. Rev. 2010, 45, 206-219. doi:10.1080/00387011003601044.

[43] Lanzarotta A, Witkowski M, Ranieri N, Albright D, Jin L, Kimani M. Analytical Tools for Examining Counterfeit Drug Products. In Trends in Counterfeit Drugs; Elkins KM, Ed.; CRC Press: Boca Raton, FL, USA, 2023; doi:10.1201/9781003183327-8.

[44] Arunkumar R, Drummond CJ, Greaves TL. FTIR spectroscopic study of the secondary structure of globular proteins in aqueous protic ionic liquids. Front. Chem. 2019, 7, 74. doi:10.3389/fchem.2019.00074.

[45] Dong A, Huang P, Caughey WS. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 1990, 29, 3303-3308. doi:10.1021/bi00465a022.

[46] Singh BR (Ed.). Basic aspects of the technique and applications of infrared spectroscopy of peptides and proteins. In Infrared Analysis of Peptides and Proteins: Principles and Applications; American Chemical Society: Washington, DC, USA, 2000; pp. 2-37.

[47] Barth A. Infrared spectroscopy of proteins. Biochim. Et Biophys. Acta 2007, 1767, 1073-1101. doi:10.1016/j.bbabio.2007.06.004.

[48] Kong J, Yu S. Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim. Et Biophys. Sin. 2007, 39, 549-559. doi:10.1111/j.1745-7270.2007.00320.x.

[49] Derenne A, Derfoufi K-M, Cowper B, Delporte C, Goormaghtigh E. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies. Anal. Chim. Acta 2020, 1112, 62-71. doi:10.1016/j.aca.2020.03.038.

[50] Godzo H, Gigopulu O, Acevska J, Geskovski N, Poceva Panovska A, Acevski B, et al. Application of ATR-FTIR as a screening method for analysis of biopharmaceutical preparations containing trastuzumab. Maced. Pharm. Bull. 2023, 69(Suppl. S1), 253-254. doi:10.33320/maced.pharm.bull.2023.69.03.124.

[51] Groß PC, Zeppezauer M. Infrared spectroscopy for biopharmaceutical protein analysis. J. Pharm. Biomed. Anal. 2010, 53, 29-36. doi:10.1016/j.jpba.2010.03.009.

[52] Yang S, Zhang Q, Yang H, Shi H, Dong A, Wang L, et al. Progress in infrared spectroscopy as an efficient tool for predicting protein secondary structure. Int. J. Biol. Macromol. 2022, 206, 175-187. doi:10.1016/j.ijbiomac.2022.02.104.

[53] Afzal MA, Bhojane PP, Rathore AS. A simple, rapid, and robust “on-the-go” identity testing of biotherapeutics using FTIR spectroscopy. Electrophoresis 2021, 42, 1655-1664. doi:10.1002/elps.202170101.

[54] Hunt NT. 2D-IR spectroscopy: Ultrafast insights into biomolecule structure and function. Chem. Soc. Rev. 2009, 38, 1837-1848. doi:10.1039/b819181f.

[55] Farmer AL, Brown K, Hunt NT. Spectroscopy 2050—The future of ultrafast 2D-IR spectroscopy. Vib. Spectrosc. 2024, 134, 103709. doi:10.1016/j.vibspec.2024.103709.

[56] Ozaki Y. Infrared Spectroscopy—Mid-infrared, Near-infrared, Far-infrared/Terahertz Spectroscopy. Anal. Sci. 2021, 37, 1193-1212. doi:10.2116/analsci.20R008.

[57] Foli LP, Hespanhol MC, Cruz KAML, Pasquini C. Miniaturized Near-Infrared spectrophotometers in forensic analytical science—A critical review. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2024, 315, 124297. doi:10.1016/j.saa.2024.124297.

[58] Varela Morillas Á, Frascione N. Investigating handheld near-infrared spectroscopy for forensic body fluid analysis. Sci. Justice 2025, 65, 101259. doi:10.1016/j.scijus.2025.101259.

[59] Gerzon G, Sheng Y, Kirkitadze M. Process Analytical Technologies—Advances in bioprocess integration and future perspectives. J. Pharm. Biomed. Anal. 2022, 207, 114379. doi:10.1016/j.jpba.2021.114379.

[60] Kalyanaraman R, Chauhan M, Madarang CJ, Ribick M, Dobler G. Screening and Detecting Counterfeit Biologics Drugs. BioPharma Asia, January/February. 2013. Available online: https://biopharma-asia.com/magazine-articles/screening-and-detecting-counterfeit-biologics-drugs/ (accessed on 21 May 2025).

[61] Ma TM, Huang RH, Collins VI, Wikström M, Batabyal D. Advancement of microfluidic modulation spectroscopy as a highly sensitive protein characterization technique for the detection of small structural changes. Anal. Biochem. 2023, 683, 115350. doi:10.1016/j.ab.2023.115350.

[62] Liu LL, Wang L, Zonderman J, Rouse JC, Kim H-Y. Automated, high-throughput infrared spectroscopy for secondary structure analysis of protein biopharmaceuticals. J. Pharm. Sci. 2020, 109, 3223-3230. doi:10.1016/j.xphs.2020.07.030.

[63] Yang Y, Yu C, Duan M, Liu C, Li M, Wu G, et al. Application of microfluidic modulation spectroscopy for simultaneous structural and thermal stability analysis of commercial mAbs under varying formulation conditions. Anal. Methods 2025, 17, 4087-4093. doi:10.1039/d4ay02324b.

[64] Vandenabeele P. Practical Raman Spectroscopy: An Introduction, 1st ed.; Wiley: Chichester, UK, 2013; pp. 1-38.

[65] Malik S, Trivedi MU, Soni GK, Sharma RK. Elucidation of protein function using Raman spectroscopy. In Analytical Techniques for the Elucidation of Protein Function; Suetake I, Sharma RK, Hojo H, Eds.; John Wiley & Sons: Hoboken, NJ, USA, 2023; pp. 69-100.

[66] Paudel A, Raijada D, Rantanen J. Raman spectroscopy in pharmaceutical product design. Adv. Drug Deliv. Rev. 2015, 89, 3-20. doi:10.1016/j.addr.2015.04.003.

[67] Kammrath BW, Leary PE, Crocombe RA. Detection and Analysis of Counterfeit Drugs. In Trends in Counterfeit Drugs; Elkins K, Ed.; CRC Press: Boca Raton, FL, USA, 2023. doi:10.1201/9781003183327-6.

[68] Wharton CW. Infra-red and Raman spectroscopic studies of enzyme structure and function. Biochem. J. 1986, 233, 25-36. doi:10.1042/bj2330025.

[69] Nemecek D, Stepanek J, Thomas GJ, Jr. Raman spectroscopy of proteins and nucleoproteins. Curr. Protoc. Protein Sci. 2013, 71, 17.8.1-17.8.52. doi:10.1002/0471140864.ps1708s71.

[70] Wen ZQ. Raman spectroscopy of protein pharmaceuticals. J. Pharm. Sci. 2007, 96, 2861-2878. doi:10.1002/jps.20895.

[71] McAvan BS, Bowsher LA, Powell T, O’Hara JF, Spitali M, Goodacre R, et al. Raman spectroscopy to monitor post-translational modifications and degradation in monoclonal antibody therapeutics. Anal. Chem. 2020, 92, 10381-10389. doi:10.1021/acs.analchem.0c00627.

[72] Nitika N, Chhabra H, Rathore AS. Raman spectroscopy for in situ, real time monitoring of protein aggregation in lyophilized biotherapeutic products. Int. J. Biol. Macromol. 2021, 15, 309-313. doi:10.1016/j.ijbiomac.2021.02.214.

[73] Massei A, Falco N, Fissore D. Use of Raman spectroscopy and PCA for quality evaluation and out-of-specification identification in biopharmaceutical products. Eur. J. Pharm. Biopharm. 2024, 200, 114342. doi:10.1016/j.ejpb.2024.114342.

[74] Saggu M, Liu J, Patel A. Identification of subvisible particles in biopharmaceutical formulations using Raman spectroscopy provides insight into polysorbate 20 degradation pathway. Pharm. Res. 2015, 32, 2877-2888. doi:10.1007/s11095-015-1670-x.

[75] Wei B, Woon N, Dai L, Fish R, Tai M, Handagama W, et al. Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics. mAbs 2022, 14, e2007564. doi:10.1080/19420862.2021.2007564.

[76] Peters J, Luczak A, Ganesh V, Park E, Kalyanaraman R. Raman Spectral Fingerprinting for Biologics Counterfeit Drug Detection. American Pharmaceutical Review. 2016. Available online: https://www.americanpharmaceuticalreview.com/Featured-Articles/184359-Raman-Spectral-Fingerprinting-For-Biologics-Counterfeit-Drug-Detection/ (accessed on 12 June 2025).

[77] Dégardin K, Desponds A, Roggo Y. Protein-based medicines analysis by Raman spectroscopy for the detection of counterfeits. Forensic Sci. Int. 2017, 278, 313-325. doi:10.1016/j.forsciint.2017.07.012.

[78] Mikhonin A, Hodi S.Detection of Counterfeit Biologic Drugs: Using 532 nm Handheld Raman. BioTools, Inc. 2023. Available online: https://biotools.us/wp-content/uploads/2023/07/biotools_counterfeitbiologics_white_paper.pdf (accessed on 12 June 2025).

[79] Dazzi A, Prater CB. AFM-IR: Technology and Applications in Nanoscale Infrared Spectroscopy and Chemical Imaging. Chem. Rev. 2017, 117, 5146-5173. doi:10.1021/acs.chemrev.6b00448.

[80] Forney-Stevens KM, Pelletier MJ, Shalaev EY, Pikal MJ, Bogner RH. Optimization of a Raman microscopy technique to efficiently detect amorphous-amorphous phase separation in freeze-dried protein formulations. J. Pharm. Sci. 2014, 103, 2749-2758. doi:10.1002/jps.23882.

[81] Tiernan H, Byrne B, Kazarian S. ATR-FTIR spectroscopy and spectroscopic imaging for the analysis of biopharmaceuticals. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2020, 241, 118636. doi:10.1016/j.saa.2020.118636.

[82] Silge A, Weber K, Cialla-May D, Müller-Botticher L, Fischer D, Popp J. Trends in pharmaceutical analysis and quality control by modern Raman spectroscopic techniques. TrAC Trends Anal. Chem. 2022, 153, 116623. doi:10.1016/j.trac.2022.116623.

[83] Shah KC, Shah MB, Solanki SJ, Makwana VD, Sureja DK, Gajjar AK, et al. Recent advancements and applications of Raman spectroscopy in pharmaceutical analysis. J. Mol. Struct. 2023, 1278, 134914. doi:10.1016/j.molstruc.2023.134914.

[84] Bitra VS, Verma S, Rao BT. TinyML-Raman: A novel IoT based field-deployable spectra analysis for accurate identification of pharmaceuticals and trace dye-pesticide mixtures from facile SERS method. Anal. Chim. Acta 2024, 1322, 343063. doi:10.1016/j.aca.2024.343063.

[85] Sacre PY, Deconinck E, De Beer T, Courselle P, Vancauwenberghe R, Chiap P, et al. Comparison and combination of spectroscopic techniques for the detection of counterfeit medicines. J. Pharm. Biomed. Anal. 2010, 53, 445-453. doi:10.1016/j.jpba.2010.05.012.

[86] Li L, Zang H, Li J, Chen D, Li T, Wang F. Identification of anisodamine tablets by Raman and near-infrared spectroscopy with chemometrics. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2014, 127, 91-97. doi:10.1016/j.saa.2014.02.022.

[87] World Health Organisation. Report of Existing Technologies Used to Screen and Detect Substandard and Falsified Medical Products; World Health Organization: Geneva, Switzerland, 2025. Available online: https://iris.who.int/bitstream/handle/10665/380876/9789240103559-eng.pdf?sequence=1 (accessed on 14 June 2025).

[88] Deidda R, Sacre PY, Clavaud M, Coïc L, Avohou H, Hubert P, et al. Vibrational spectroscopy in analysis of pharmaceuticals: Critical review of innovative portable and handheld NIR and Raman spectrophotometers. Trends Anal. Chem. 2019, 114, 251-259. doi:10.1016/j.trac.2019.02.035.

[89] Ling J, Zheng L, Xu M, Chen G, Wang X, Mao D, et al. Extreme point sort transformation combined with a long short-term memory network algorithm for the Raman-based identification of therapeutic monoclonal antibodies. Front. Chem. 2022, 10, 887960. doi:10.3389/fchem.2022.887960.